Novotech Opens Tokyo Office, Strengthening Japan Presence

Editor’s Take: This office enhances Novotech’s ability to support Japanese biopharma companies as they advance their products.

Novotech, a global biotech CRO and full-service clinical research organization, has opened a new office in Tokyo. The company already has established operations and clinical trial activity in Japan, so this office strengthens Novotech’s presence there.

Novotech is supporting ongoing studies in Japan, plus providing sponsors with integrated support in Australia, the United States, and elsewhere. Altogether, Novotech boosts its ability to impact cross-border clinical trials, connecting sponsors in the Asia-Pacific region, the U.S., and Europe.

Novotech Gets Stronger in Japan

Moreover, the Tokyo office enhances Novotech’s ability, according to the company, to support Japanese biopharmaceutical companies. With this expansion, those companies can interface with Novotech to advance programs regionally as well as across key international markets.

Novotech sees the Tokyo office as its strategic operations hub—strengthening partnerships with clients, research institutions, and “innovation ecosystems.” This is especially important as Japan’s pharmaceutical market is characterized by a sophisticated research base and rapidly evolving biotech sector.

“The opening of our Tokyo office is an important milestone for Novotech,” Takeshi Mori, Country Head, Japan, said. “Japan is a critical market for global clinical development. This investment reflects our long-term commitment to building strong local capabilities while delivering high-quality services to our clients.”

Beyond Tokyo

Globally, Novotech says its operating model aligns well with the needs of emerging and growth-stage biopharma companies. The company is able to provide flexible, high-quality clinical development support, without multiple regional provider complexity.

Therapeutic areas of expertise for Novotech include oncology, rare diseases, central nervous system disorders, infectious diseases, immunology, and advanced therapies. Furthermore, regulatory, scientific, and operational expertise supports the company across major clinical trial markets.